Abstract:A series of 17-cyclopropylmethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 alpha-(isoquinoline-3 '-carboxamido)morphinan (NAQ) analogues were synthesized and pharmacologically characterized to study their structure-activity relationship at the mu opioid receptor (MOR). The competition binding assay showed two-atom spacer and aromatic side chain were optimal for MOR selectivity. Meanwhile, substitutions at the 1 '- and/or 4 '-position of the isoquinoline ring retained or improved MOR selectivity over the kappa opioid receptor while still possessing above 20-fold MOR selectivity over the delta opioid receptor. In contrast, substitutions at the 6 '- and/or 7 '-position of the isoquinoline ring reduced MOR selectivity as well as MOR efficacy. Among this series of ligands, compound 11 acted as an antagonist when challenged with morphine in warm-water tail immersion assay and produced less significant withdrawal symptoms compared to naltrexone in morphine-pelleted mice. Compound 11 also antagonized the intracellular Ca2+ increase induced by DAMGO. Molecular dynamics simulation studies of 11 in three opioid receptors indicated orientation of the 6 '-nitro group varied significantly in the different 'address' domains of the receptors and played a crucial role in the observed binding affinities and selectivity. Collectively, the current findings provide valuable insights for future development of NAQ-based MOR selective ligands. Published by Elsevier Ltd.

(9S,13R,14R)-7,8-Didehydro-3,4,7-trimeth-oxy-17-methyl-morphinan-6-one.

(R)-(+)-3-hydroxy-2-methoxycarbonyl-8-methyl-8-azoniabicyclo[3.2.1]octane L-Bitartrate

(3ar,6s,7s,7ar)-2-(4-Methoxybenzyl)-7-(4-Nitrophenyl)-6-Phenyl-3a,6, 7,7a-Tetrahydroisoindolin-1-One

(1S,3as,4s,7as)-Ethyl 1-Benzyl-2-(4-methoxybenzyl)-6,7-dimethyl-3-oxo-2,3,3a,4,5,7a-hexahydro-1h-isoindole-4-carboxylate Dichloromethane Monosolvate

4-(Benzoylthiocarbonyl)morpholine

Dimethyl 2-(4-Fluorophenyl)-3-(methylamino)-furan-4,5-dicarboxylate

(1<i>S</i>,4a<i>R</i>,5<i>S</i>,6<i>S</i>,8a<i>R</i>*)-3-Benzyl-1-methyl-5,6-diphenyl-3,4,4a,5,6,8a-hexahydro-1<i>H</i>-2,3-benzoxazin-4-one

(1S,4aR,5S,6S,8aR*)-3-Benzyl-1-methyl-5,6-diphenyl-3,4,4a,5,6,8a-hexa-hydro-1H-2,3-benzoxazin-4-one.

(±)-(3aRS,4SR)-9-Chloro-2-(2-chloro-4-nitrophenyl)-4-(4-chlorophenyl)-3a,4-diethoxy-6,8-dimethoxychromano[4,3-d]-Δ1,9b-1,2,3-thiadiazoline

(1R,4s,8r,9r,12s,13s,14r,16s,17r,19r)-17-[(ethylsulfanyl)methyl]-9,14-dihydroxy-7,7-dimethyl-2,18-dioxo-3,10-dioxapentacyclo[14.2.1.01,13.04,12.08,12]nonadecan-19-yl Acetate Acetone Solvate

Octahydro-7a,8′-dimethylspiro[isobenzofuran-4(1H),4′(3′H)-[1H-7,9a]methanocyclohepta[c]pyran]-1′,3,9′(3aH,4′aH)-trione

4-(3,4-Dimethoxyphenyl)-2-oxo-n,3-bis(3,4,5-trimethoxyphenyl)-2,3-dihydro-1h-imidazoline-1-carboxamide

N-[2-(2-Methoxyphenyl)benzylidene]-tert-butyl-amine N-oxide.

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

(E)-Dimethyl 4-(Ethylamino)-5-styrylfuran-2,3-dicarboxylate

(3As,4s,5r,7as,1 ' R,2a ' S,6 ' S,6a ' S)-5-(2 ',5 '-Dioxo-2a '-Methyl-6 ',6a '-Epoxyperhydroinden-1 '-Yl)-3a,4-epoxy-5-hydroxy-7a-methylperhydro-1h-inden-1-one

N-Cyclo-hexyl-5H,7H-13,15-dimethyl-9-nitro-5-oxophenanthrido[4,4a,5-bc][1,4]benzoxazepine-7-carboxamide.

1-Ethyl-2-oxo-5-phenyl-1,6-dihydro-2h-oxazolo[4′,5′:5,6]Pyrido[3,4-b]indole Methanol Hemisolvate

Synthesis of (+)-C-Normorphinan Analogs Starting from Sinomenine

Design, Syntheses, and Pharmacological Characterization of 17-Cyclopropylmethyl-3,14 Beta-Dihydroxy-4,5 Alpha-Epoxy-6 Alpha-(Isoquinoline-3 '-Carboxamido)morphinan Analogues As Opioid Receptor Ligands

2-(4,6-Dimethoxypyrimidin-2-ylsulfanyl)-n-phenylbenzamide